126 related articles for article (PubMed ID: 36610879)
1. Re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
García Nader S; Peña Rodríguez S; Diaz Ritter CA
Eur Urol; 2023 Apr; 83(4):e103. PubMed ID: 36610879
[No Abstract] [Full Text] [Related]
2. Reply to Sandra Patricia García Nader, Sebastián Peña Rodríguez, and Cesar Alejandro Diaz Ritter's Letter to the Editor re: Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, et al. Prostate-specific Antigen Screening in Transgender Patients. Eur Urol. 2023;83:48-54.
Nik-Ahd F; Cooperberg MR; Freedland SJ
Eur Urol; 2023 Apr; 83(4):e104. PubMed ID: 36653258
[No Abstract] [Full Text] [Related]
3. Re: Deebel et al.: Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges (Urology 2017;110:166-171).
Nguyen A; O'Leary MP
Urology; 2018 Jan; 111():240. PubMed ID: 29051006
[No Abstract] [Full Text] [Related]
4. Reply from Authors re: Andrew J. Vickers, Michael J. Pencina. Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. Eur Urol 2013;64:394-6: prostate-specific antigen velocity: new unscreened cohort, natural history of prostate cancer, room for different interpretations.
Ørsted DD; Bojesen SE; Kamstrup PR; Nordestgaard BG
Eur Urol; 2013 Sep; 64(3):396-7. PubMed ID: 23571004
[No Abstract] [Full Text] [Related]
5. Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
Leppert JT; Brooks JD
Eur Urol; 2018 Nov; 74(5):e110-e111. PubMed ID: 30017399
[No Abstract] [Full Text] [Related]
6. Re: Giorgio Gandaglia G, Peter Albers, Per-Anders Abrahamsson, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. Eur Urol 2019;76:142-50.
Froehner M; Koch R; Thomas C
Eur Urol; 2020 Jan; 77(1):e30. PubMed ID: 31836073
[No Abstract] [Full Text] [Related]
7. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
Goonewardene SS; Persad R; Young A; Makar A
Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
[No Abstract] [Full Text] [Related]
8. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
Connolly D; Hutton R; Keane PF
Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
[No Abstract] [Full Text] [Related]
9. Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
Anand M; Jain B; Aggarwal S
Eur Urol; 2024 May; 85(5):e145. PubMed ID: 38092614
[No Abstract] [Full Text] [Related]
10. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
Morrod D
Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
[No Abstract] [Full Text] [Related]
11. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.
Penney KL; Loda M; Stampfer MJ
Eur Urol; 2019 Mar; 75(3):e54-e55. PubMed ID: 30322655
[No Abstract] [Full Text] [Related]
12. Re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
Tadtayev S; McNicholas TA; Boustead GB
Eur Urol; 2012 Jul; 62(1):e14-5; author reply e16-7. PubMed ID: 22537798
[No Abstract] [Full Text] [Related]
13. Re: Baris Turkbey, Andrew B. Rosenkrantz, Masoom A. Haider, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76:340-51.
Park BK
Eur Urol; 2019 Sep; 76(3):e78. PubMed ID: 31186172
[No Abstract] [Full Text] [Related]
14. Re: Sigrid V. Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2023;83:103-9.
Kim KM; Kim JH; Chung BI
Eur Urol; 2023 May; 83(5):e137-e138. PubMed ID: 36774223
[No Abstract] [Full Text] [Related]
15. Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes-A Report from a Consensus Meeting. Eur Urol 2015;67:771-7.
Kamrava M
Eur Urol; 2015 Jul; 68(1):e14. PubMed ID: 25703574
[No Abstract] [Full Text] [Related]
16. Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
Takahashi T
Eur Urol; 2022 Jan; 81(1):e22. PubMed ID: 34716050
[No Abstract] [Full Text] [Related]
17. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
Mahal BA; Yang DD; Nguyen PL
Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
[No Abstract] [Full Text] [Related]
18. Re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648-656.
Jue JS; Alameddine M
Eur Urol Oncol; 2020 Oct; 3(5):710. PubMed ID: 31882350
[No Abstract] [Full Text] [Related]
19. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
Temiz MZ; Besiroglu H
Eur Urol; 2018 May; 73(5):e130. PubMed ID: 29397220
[No Abstract] [Full Text] [Related]
20. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7.
Dal Pra A; Supiot S; Ghadjar P
Eur Urol; 2018 Feb; 73(2):e34-e35. PubMed ID: 28890243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
